Legal Counsel
Novo Nordisk is hiring a Legal Counsel to join their Global Legal, Intellectual Property, and Security (GLIPS) department in Bengaluru. This role will specifically support the R&D legal team by managing the end-to-end contracting process, identifying risks, and driving process improvements. The ideal candidate brings 8-10 years of experience in global corporate legal functions with strong drafting and CLM skills. The position emphasizes proactive support and standardizing legal workflows for the R&D division.
50k new jobs listed every day. Install TAL to find more jobs like this.
Experience
8-10 years
Function
Research
Work mode
Onsite, India
Company
Tier 1
What you will work on
Novo Nordisk is hiring a Legal Counsel to join their Global Legal, Intellectual Property, and Security (GLIPS) department in Bengaluru. This role will specifically support the R&D legal team by managing the end-to-end contracting process, identifying risks, and driving process improvements. The ideal candidate brings 8-10 years of experience in global corporate legal functions with strong drafting and CLM skills. The position emphasizes proactive support and standardizing legal workflows for the R&D division.
TAL's take
High-caliber global healthcare firm offering a specialized legal role in a newly established R&D focused team.
Clearly defined scope, responsibilities, and experience requirements within the GBS legal department.
Salaries at Novo Nordisk
19.3 LPA average
Based on 19 Grapevine salary entries for Novo Nordisk.
Other roles
0 - 2 years
4 LPA average
Range: 4 - 4 LPA
Product Management
2 - 4 years | 6
14 LPA average
Range: 14 - 14 LPA
Other roles
2 - 4 years | 6
17 LPA average
Range: 17 - 17 LPA
Operations
4 - 6 years | L5
10 LPA average
Range: 10 - 10 LPA
Must haves
- Master’s or bachelor’s degree in law
- 8–10 years of experience supporting legal function in global corporations
- Expertise in drafting, reviewing, and redlining commercial contracts
- Experience managing end-to-end Contract Lifecycle Management (CLM) process
- Understanding of contractual terms, risk identification, and mitigation
Tools and skills
Nice to have: contract management tools, clm tools.
About the company
Global leading healthcare corporation with significant market presence and scale.
Posts mentioning Novo Nordisk
Amgen's Weight-Loss Drug Falls Short, Stock Plummets
- Amgen's MariTide Phase-2 data showed 20% weight loss at 52 weeks, but stock dropped 13.31% pre-market. - Rival stocks Eli Lilly and Novo Nordisk rose on Biden's proposal for expanded Medicare, Medicaid coverage for obesity drugs. - Retail investors remain bullish on Amgen despite analyst disappointment. Source: [Asianet Newsable](https://newsable.asianetnews.com/markets/amgen-stock-sinks-on-modest-obesity-drug-results-but-retail-sentiment-remains-steady-snk9xh), [Asianet Newsable](https://newsable.asianetnews.com/markets/eli-lilly-novo-nordisk-shares-climb-premarket-as-biden-administration-mulls-medicare-medicaid-covering-for-obesity-drugs-retail-unmoved-snk72g)
The Controversial Rise of Weight Loss Drugs
- Weight loss drugs like OIC, Zep bound, and Monaro are becoming increasingly popular, despite high costs. - These drugs, also known as glucagon-like peptide one drugs, mimic a natural hormone that affects brain signals on appetite and hunger. - The potential market for obesity medication is massive, with some speculating it could be more lucrative than any other class of drug. - Pharmaceutical companies are pushing for obesity to be classified as a disease, which could open up a market worth trillions of dollars. - However, there are concerns about the ethics of these companies, particularly given the history of the opioid epidemic. - Companies like Eli Lily and Novo Nordisk are leading the way in this new class of drugs, with their share prices and market caps increasing significantly. Source: [Modern MBA](https://www.youtube.com/watch?v=7sUoZVke_30&ab_channel=ModernMBA)
The Looming Fiscal Crisis Over Revolutionary Weight Loss Drugs
- America faces a fiscal crisis over revolutionary weight loss drugs like Ozempic and Wegovy. - These drugs, produced by Novo Nordisk, have potential cardiovascular, mental health, and anti-cancer benefits. - However, their high cost in the U.S. compared to other countries could bankrupt Medicare. - If half of U.S. adults with obesity took these drugs, it would cost $411 billion annually. - The State Treasurer of North Carolina, Dale Folwell, is questioning the high cost and has asked the federal government to negotiate with Novo Nordisk to open up patents to generic manufacturers. Source: [More Perfect Union](https://youtu.be/JqHmvMjXuro)